FLNA Filana Therapeutics Inc

Price (delayed)

$1.4

Market cap

$67.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.61

Enterprise value

-$18.94M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical ...

Highlights
Filana Therapeutics's EPS has increased by 14% from the previous quarter but it has decreased by 5% YoY
The net income has grown by 14% from the previous quarter but it has contracted by 7% YoY
The quick ratio has dropped by 76% year-on-year
Filana Therapeutics's equity has decreased by 47% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of FLNA

FLNA stock price

How has the Filana Therapeutics stock price performed over time
Intraday
2.94%
1 week
-9.68%
1 month
0%
1 year
-34.88%
YTD
-29.29%
QTD
-17.16%

Financial performance

How have Filana Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.97M
Net income
-$77.9M
Gross margin
N/A
Net margin
N/A
Filana Therapeutics's operating income has increased by 44% YoY and by 14% from the previous quarter
The net income has grown by 14% from the previous quarter but it has contracted by 7% YoY

Price vs fundamentals

How does FLNA's price correlate with its fundamentals

Growth

What is Filana Therapeutics's growth rate over time

Valuation

What is Filana Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Filana Therapeutics's EPS has increased by 14% from the previous quarter but it has decreased by 5% YoY
FLNA's P/B is 82% below its 5-year quarterly average of 5.2 and 26% below its last 4 quarters average of 1.3
Filana Therapeutics's equity has decreased by 47% YoY and by 8% from the previous quarter

Efficiency

How efficient is Filana Therapeutics business performance
FLNA's return on equity has dropped by 116% year-on-year
Filana Therapeutics's ROA has plunged by 67% YoY but it has increased by 9% from the previous quarter

Dividends

What is FLNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLNA.

Financial health

How did Filana Therapeutics financials performed over time
The total assets is 169% more than the total liabilities
The quick ratio has dropped by 76% year-on-year
The current ratio has plunged by 76% YoY
Filana Therapeutics's debt is 100% less than its equity
Filana Therapeutics's equity has decreased by 47% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.